➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Mallinckrodt
Dow
Harvard Business School

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201917

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 201917 describes INCIVEK, which is a drug marketed by Vertex Pharms and is included in one NDA. There are three patents protecting this drug. Additional details are available on the INCIVEK profile page.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this compound. Additional details are available on the telaprevir profile page.
Summary for 201917
Tradename:INCIVEK
Applicant:Vertex Pharms
Ingredient:telaprevir
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 201917
Generic Entry Date for 201917*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength375MG
Approval Date:May 23, 2011TE:RLD:No
Patent:  Start TrialPatent Expiration:Feb 25, 2025Product Flag?YSubstance Flag?YDelist Request?
Patent:  Start TrialPatent Expiration:May 30, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING CHRONIC HEPATITIS C
Patent:  Start TrialPatent Expiration:Aug 31, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING CHRONIC HEPATITIS C

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
Dow
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.